Sign in

INTI on OTC

Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Tampa, Florida.1 Its shares trade on OTC under the symbol INTI.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerINTI on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersTampa, Florida1
  • Incorporated inDE2
  • Business address4830 W. Kennedy Blvd., Suite 600, Tampa, Fl 336092
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue34$0 in 2021
02019: $0$020192020: $0$020202021: $0$02021
Operating income345-$325.4K in 2021−88% since 2019
-$3.0M-$2.0M-$1.0M02019: -$2.7M-$2.7M20192020: -$1.1M-$1.1M2020−61%2021: -$325.4K-$325.4K2021−69%
Net income345-$298.6K in 2021−89% since 2019
-$3.0M-$2.0M-$1.0M02019: -$2.7M-$2.7M20192020: -$1.1M-$1.1M2020−61%2021: -$298.6K-$298.6K2021−72%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$1.7M$1.8M
General and administrative$1.7M$1.9M
Total expenses$3.4M$3.7M
Loss from operations-$3.4M-$3.7M
Interest income$126.3K$318.2K
Net loss-$3.3M-$3.3M
Basic net loss per share-$0.02-$0.02
Diluted net loss per share-$0.02-$0.02
Weighted average common stock shares outstanding - basic172.5M shares172.3M shares
Weighted average common stock shares outstanding - diluted172.5M shares172.3M shares

Compare Inhibitor Therapeutics, Inc. with another company

Corporate structure

Inhibitor Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inhibitor Therapeutics, Inc.

  • Inhibitor Therapeutics, Inc. Tampa, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inhibitor Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$64.3K8 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.4M8 Dec 31, 2025$5.6M8 Dec 31, 2024−57.6%

Properties, in its own words

Our principal executive offices are located at 3014 West Palmira Avenue, Suite 302, Tampa, Florida 33629. We believe our current facilities are adequate for our present needs.

Item 2 of the 10-K filed Mar 26, 2026.10

Leadership

Who has led Inhibitor Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert B. Harris2006–2007
  2. Nick Hagan2007
  3. Paul D'Sylva2007
  4. Garrison J. Hasara2013
  5. Nicholas J. Virca2013–2020
  6. Francis E. Odonnell Jr.2026–now

Chair

  1. William X. Guo2008
  2. Francis E. Odonnell Jr.2013–2016
  3. E. Brendan Magrab2016–2018

President

  1. Robert B. Harris2006–2009
  2. Nicholas J. Virca2013–2020

Chief financial officer

  1. Garrison J. Hasara2015–2020
  2. James A. McNulty2024–now
2010201520202025
Board members and other officers (23)

Former names

  • HedgePath Pharmaceuticals, Inc.Aug 16, 2013 to Aug 12, 20192
  • COMMONWEALTH BIOTECHNOLOGIES INCOct 7, 1997 to May 20, 20132

Timeline

  1. Sep 18, 20268-K Executive or director change; Shareholder vote39
  2. Aug 4, 2026New chief executive Francis E. Odonnell Jr. becomes CEO11
  3. Apr 1, 20268-K Other events40
  4. Apr 1, 20268-K Regulation FD disclosure41
  5. Feb 24, 20268-K Entered a material agreement42
  6. Oct 27, 20258-K Entered a material agreement; Executive or director change43
  7. Dec 14, 20238-K Entered a material agreement; Other events44
  8. Oct 18, 20238-K Executive or director change; Bylaws or fiscal year changed45
  9. Aug 29, 20238-K Executive or director change; Bylaws or fiscal year changed46
  10. May 31, 20238-K Executive or director change47
  11. Dec 19, 20228-K Entered a material agreement; Ended a material agreement; Change in control48
  12. Sep 15, 20228-K Other events49
  13. Jun 3, 20228-K Executive or director change50
  14. Aug 21, 2013New chief executive Nicholas J. Virca becomes CEO13
  15. Aug 21, 2013New chief executive Garrison J. Hasara becomes CEO12
  16. Feb 13, 2007New chief executive Paul D'Sylva becomes CEO15
  17. Feb 13, 2007New chief executive Nick Hagan becomes CEO14
  18. Feb 8, 2006New chief executive Robert B. Harris becomes CEO16

Filings

70 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 13 major events, 30 insider forms, 3 large holders, 4 other. The latest 20:

  1. Sep 18, 20268-K EDGAR
  2. Aug 17, 2026DEF 14A EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Aug 4, 20264 EDGAR
  5. Aug 4, 20264 EDGAR
  6. Aug 4, 20264 EDGAR
  7. Aug 4, 20264 EDGAR
  8. Aug 4, 20264 EDGAR
  9. Jun 24, 20264 EDGAR
  10. Jun 1, 20264 EDGAR
  11. May 15, 202610-Q EDGAR
  12. Apr 1, 20268-K EDGAR
  13. Apr 1, 20268-K EDGAR
  14. Mar 26, 202610-K EDGAR
  15. Feb 24, 20268-K EDGAR
  16. Nov 13, 202510-Q EDGAR
  17. Oct 27, 20258-K EDGAR
  18. Sep 15, 2025UPLOAD EDGAR
  19. Aug 13, 202510-Q EDGAR
  20. Jul 22, 2025CORRESP EDGAR

The 70 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Francis E. O’Donnell76$598.0K$1.1M54
2025James A. McNulty76$200.0K$362.6K54
2024Executive Chairman and Chief Executive Officer$598.0K$1.1M54
2024Interim Chief Financial OfficerSecretary and Treasurer$200.0K$359.8K54

SEC filer profile

How Inhibitor Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInhibitor Therapeutics, Inc.1
  • CIK0001042418
  • Employer ID (EIN)30-079366510
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company10
  • Incorporated inDelaware10
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4830 W. Kennedy Blvd., Suite 600, Tampa, FL 336091
  • Phone(813) 766-24621
  • Shares outstanding173,791,968 as of Aug 14, 20267
  • Public float$3.3M as of Jun 30, 202510
  • AuditorCherry Bekaert LLP, Tampa, Florida PCAOB ID 677; no auditor attestation of internal control over financial reporting10
  • On EDGAR sinceJul 21, 19971
  • Filings724 in all: 8-K (200), 4 (168), 10-Q (55), 10QSB (32), 3 (29), SC 13D/A (22), 10-K (19), DEF 14A (15)1
    All 52 form types

    UPLOAD (14), 5 (12), 8-K/A (11), 10KSB (10), 4/A (10), SC 13D (9), DEF 14C (8), NT 10-Q (8), CORRESP (7), CT ORDER (7), PRE 14A (7), SC 13G (7), EFFECT (6), S-1/A (6), PRE 14C (5), S-8 (5), 10QSB/A (4), NT 10-K (4), POS AM (4), REGDEX (4), S-1 (3), S-3 (3), SB-2/A (3), 10KSB/A (2), 424B3 (2), NO ACT (2), PRER14A (2), S-8 POS (2), SB-2 (2), 15-12B (1), 15-12B/A (1), 25-NSE (1), 424B1 (1), 8-A12B (1), D (1), DEFR14A (1), DEFS14A (1), DFAN14A (1), NTN 10Q (1), PREM14A (1), PRES14A (1), RW (1), S-3/A (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 17, 2026
    Latest 8-K (8-K) Sep 18, 2026

Risk factors and legal proceedings

The risks Inhibitor Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 36 risks under these headings, as written.10

  • Risks Relating to Our Business
  • We presently conduct only minimal operations. We are also subject to the risks associated with early-stage businesses in the pharmaceutical industry.
  • Our limited operating history makes it difficult for you to evaluate our business to date and to assess our future viability.
  • We are dependent upon our officers and directors and their loss could adversely affect our ability to operate.
  • Our business and operations would suffer in the event of system failures.
  • Risks Related to Our Financial Position and Need For Additional Capital
  • We have no cash generating operations and may consume resources faster than expected.
  • Raising additional capital or issuing new securities in connection with strategic transactions may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • We might not be able to continue as a going concern.
  • Risks Related to the Clinical Development of Our Product Candidate
  • We are early in our development efforts. Although we were able to settle our recent extended litigation and have adequate cash for near-term planned operations, if we are unable to clinically develop and ultimately commercialize Itraconazole or other product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidate.
The other 27 risks
  • If we experience delays or difficulties in enrollment of patients in any future clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
  • If serious adverse or unacceptable side effects are identified during the development of our product candidate, we may need to abandon or limit such development, which would adversely affect our company.
  • We expect to rely on collaborations with third parties for key aspects of our business. If we are unable to secure or maintain any of these collaborations, or if these collaborations do not achieve their goals, our business could be adversely affected.
  • Risks Related to the Commercialization of Our Product Candidates
  • Even if any of our product candidates receive marketing approval for any indication, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
  • If we are unable to establish sales, marketing and distribution capabilities, we may not be able to commercialize our product candidate if and when it is approved.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to commercialize our technology and products may be impaired.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
  • We have licensed or expect to license certain intellectual property from third parties, and such licenses may not continue to be available or may not be available on commercially reasonable terms.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business.
  • If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose rights that are important to our business.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • Risks Related to Regulatory Approval of Our Product Candidates and Other Legal and Compliance Matters
  • If we fail to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidate, and our ability to generate revenue and the viability of our company will be materially impaired.
  • Risks Related to Our Securities
  • An active trading market for our common stock does not exist and may not develop or be sustained.
  • We may not maintain qualification for OTCQB inclusion, and therefore you may be unable to sell your shares.
  • Even if a market for our common stock develops, the market price of our common stock may be significantly volatile, which could result in substantial losses for purchasers.
  • Our management and three significant stockholders collectively own a substantial majority of our common stock and voting power.
  • Future sales of our common stock in the public market could lower the price of our common stock and impair our ability to raise funds in future securities offerings.
  • Our common stock is considered a “penny stock,” and thereby is subject to additional sale and trading regulations that may make it more difficult to sell.
  • FINRA sales practice requirements may also limit your ability to buy and sell our common stock, which could depress the price of our shares.
  • There may be limitations on the effectiveness of our internal controls, and failure of our control systems to prevent error or fraud may materially harm our company.
  • If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.
  • Anti-takeover provisions in our charter documents and Delaware law could discourage, delay or prevent a change in control of our company and may affect the trading price of our common stock.
  • We do not intend to pay dividends on our common stock.

Legal proceedings

From time to time, we may be involved in legal proceedings or claims arising in the ordinary course of business. As of the date of this report, we are not aware of any material pending legal proceeding that we believe would require disclosure in this Item, except as otherwise described elsewhere in this Annual Report, if applicable.

The opening of Item 3, Legal Proceedings.10

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54